Dr. Albert Kim
Chief Medical Officer
Albert Kim is an accomplished physician-scientist who brings more than 21 years of interdisciplinary experience in medicine and drug development across a range of therapeutic modalities. Prior to joining Cytel he held senior leadership positions at Novartis and Pfizer.
Dr. Kim has rich expertise in cardiovascular disease, translational medicine, and drug development. Most recently, he was Vice President, Clinical Research Head for Pfizer’s Internal Medicine Research Unit. His roles at Pfizer and at Novartis saw him lead early and late phase programs for common and rare diseases.
Dr. Kim has contributed to development efforts for several candidate medicines utilizing different therapeutic modalities and has authored a body of work including numerous publications in leading medical journals. He was also a medical reviewer in the Division of Cardiac Devices at the FDA.
After receiving degrees from Harvard and UCLA, completing residency at Brigham and Women's Hospital, and undertaking further specialty training at Mass General Hospital and UCSF, he achieved board certification in internal medicine, cardiology, and clinical cardiac electrophysiology.